Nexalin Technology (NXL) said Tuesday that the University of California in San Diego Institutional Review Board has approved the use of its Halo Clarity headset in human subjects in clinical trials.
The headsets will be tested in clinical trials to assess their efficacy in treating mild traumatic brain injury and post-traumatic stress disorder, particularly in military personnel, the company said.
The company and its manufacturing partner have begun preparing the initial shipment of 50 headsets to the university, which is conducting the study independently, Nexalin said.
Nexalin said the headset is a non-invasive treatment that can be used at home and allows physicians to monitor patient progress remotely.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。